Lantern Pharma discusses AI for drug development

Q: What did LTRN discuss in its September 23, 2026 webinar?

Lantern Pharma discussed its Open-Medicine AI multi-agentic AI platform for drug development.

A replay of Lantern Pharma’s September 23, 2026 webinar is available on YouTube and its investor website.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Lantern Pharma Inc. (LTRN) hosted a live webinar on September 23, 2026, discussing the Open-Medicine AI multi-agentic AI platform for drug development. A replay is available on YouTube and the company’s investor website, and the presentation used during the webinar was furnished as an exhibit.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

multi-agentic AI platform, Regulation FD, incorporated by reference

3 terms

multi-agentic AI platform technical

"Open-Medicine AI multi-agentic AI platform for drug development"

A multi-agentic AI platform is a software system where many smaller AI programs, each with a specific role, work together and communicate to solve complex problems—like an orchestra where each musician plays a part toward a single performance. Investors care because these platforms can automate and scale complicated workflows, speed product development, and reduce labor costs, which can boost revenue and margins; adoption, operational costs and technical risk determine whether those benefits actually translate into value.

Regulation FD regulatory

"Item 7.01 Regulation FD Disclosure"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

incorporated by reference regulatory

"nor shall it be deemed incorporated by reference"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LTRN discuss in its September 23, 2026 webinar?

Lantern Pharma discussed its Open-Medicine AI multi-agentic AI platform for drug development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/24/2026 - 06:01 AM Accepted by SEC EDGAR 09/23/2026 - 08:41 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 23, 2026

Lantern Pharma Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39318

46-3973463

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1920 McKinney Avenue, 7th Floor

Dallas, Texas

75201

(Address of Principal Executive Offices)

(Zip Code)

(972) 277-1136

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Common Stock

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value		LTRN		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 23, 2026, Lantern Pharma Inc. (the “Company”) hosted a live webinar to discuss the Open-Medicine AI multi-agentic AI platform for drug development.

The following is a link to a replay of the webinar: https://youtu.be/s7br8vjMk4s A replay of the webinar is also available on the investors section of the Company’s website at www.lanternpharma.com

A copy of the presentation used to assist with the Company’s discussions during the webinar is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit Description

99.1		Presentation relating to September 23, 2026 webinar discussing the Open-Medicine AI platform.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.